(UPDATED) Calling the trial conclusive, a researcher says, “We have a safe, effective intervention that can be done at low cost, low risk for patients.”
ADAPTABLE: Low-Dose Aspirin as Good as High-Dose in CHD? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
email article
A direct oral anticoagulant (DOAC) was no better than existing antithrombotic treatments after transcatheter aortic valve replacement (TAVR), according to ATLANTIS trial investigators.
TAVR patients randomized to apixaban (Eliquis) instead of antiplatelet therapy or warfarin saw no reduction in the trial s primary endpoint, a composite of death, MI, stroke, systemic emboli, intracardiac or bioprosthesis thrombus, episode of deep vein thrombosis (DVT) or pulmonary embolism (PE), and major bleeding over 1-year follow-up (18.4% vs 20.1%, HR 0.92, 95% CI 0.73-1.16).
These findings were consistent whether patients had an indication for oral anticoagulation or not, reported Jean-Philippe Collet, MD, PhD, of Pitié-Salpêtrière Hospital in Paris, at the American College of Cardiology (ACC) virtual meeting.